Xuanling R. Shi

Beijing, 100084, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications

Decoding antibody response to MERS-CoV in wild dromedary camels.

Decoding antibody response to MERS-CoV in wild dromedary camels.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 09, 2026

Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid.

Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid.

Journal: PLoS pathogens
Published: December 06, 2025

Twenty-year persistence of SARS-CoV-1 immune imprinting shapes antibody responses to SARS-CoV-2 infection.

Twenty-year persistence of SARS-CoV-1 immune imprinting shapes antibody responses to SARS-CoV-2 infection.

Journal: Immunity
Published: August 23, 2025

Identification and characterization of bone marrow plasma cells producing IFN-γ-neutralizing autoantibodies in adult-onset immunodeficiency.

Identification and characterization of bone marrow plasma cells producing IFN-γ-neutralizing autoantibodies in adult-onset immunodeficiency.

Journal: Cell reports. Medicine
Published: May 12, 2025

Mapping of Phospholipase A2 Receptor Epitopes in Idiopathic Membranous Nephropathy and Clinical Relevance of Epitope Profiles.

Mapping of Phospholipase A2 Receptor Epitopes in Idiopathic Membranous Nephropathy and Clinical Relevance of Epitope Profiles.

Journal: Journal of the American Society of Nephrology : JASN
Published: April 06, 2025

DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection.

DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection.

Journal: NPJ vaccines
Published: September 29, 2024

Super broad and protective nanobodies against Sarbecoviruses including SARS-CoV-1 and the divergent SARS-CoV-2 subvariant KP.3.1.1.

Super broad and protective nanobodies against Sarbecoviruses including SARS-CoV-1 and the divergent SARS-CoV-2 subvariant KP.3.1.1.

Journal: PLoS pathogens
Published: June 14, 2024

Exploring distinct modes of inter-spike cross-linking for enhanced neutralization by SARS-CoV-2 antibodies.

Exploring distinct modes of inter-spike cross-linking for enhanced neutralization by SARS-CoV-2 antibodies.

Journal: Nature communications
Published: May 23, 2024

CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges.

CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges.

Journal: Infectious diseases & immunity
Published: March 13, 2024

Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection.

Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection.

Journal: Immunity
Published: March 10, 2023

Novel TLR7/8 agonists promote activation of HIV-1 latent reservoirs and human T and NK cells.

Novel TLR7/8 agonists promote activation of HIV-1 latent reservoirs and human T and NK cells.

Journal: Frontiers in microbiology
Published: August 31, 2022

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses.

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses.

Journal: Nature communications
Published: August 03, 2022
Showing 1-12 of 60

Last Updated: 09/26/2026